These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4334548)

  • 1. Further characterization of the local respiratory tract antibody response induced by intranasal instillation of inactivated rhinovirus 13 vaccine.
    Buscho RF; Perkins JC; Knopf HL; Kapikian AZ; Chanock RM
    J Immunol; 1972 Jan; 108(1):169-77. PubMed ID: 4334548
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of the neutralizing activity in nasal wash and serum following intranasal vaccinaion with inactivated type 13 rhinovirus.
    Knopf HL; Perkins JC; Bertran DM; Kapikian AZ; Chanock RM
    J Immunol; 1970 Mar; 104(3):566-73. PubMed ID: 4314177
    [No Abstract]   [Full Text] [Related]  

  • 3. Demonstration and characterization of antibody in tears following intranasal vaccination with inactivated type 13 rhinovirus: a preliminary report.
    Knopf HL; Bertran DM; Kapikian AZ
    Invest Ophthalmol; 1970 Oct; 9(10):727-34. PubMed ID: 4320302
    [No Abstract]   [Full Text] [Related]  

  • 4. Broad antigenic relationships among rhinovirus serotypes revealed by cross-immunization of rabbits with different serotypes.
    Cooney MK; Wise JA; Kenny GE; Fox JP
    J Immunol; 1975 Feb; 114(2 Pt 1):635-9. PubMed ID: 47360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic relationships of common rhinovirus types from disabling upper respiratory illnesses.
    Mogabgab WJ; Holmes BJ; Pollock B
    Dev Biol Stand; 1975; 28():400-11. PubMed ID: 165120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in IgA and IgG concentrations in nasal secretions prior to the appearance of antibody during viral respiratory infection in man.
    Butler WT; Waldmann TA; Rossen RD; Douglas RG; Couch RB
    J Immunol; 1970 Sep; 105(3):584-91. PubMed ID: 4318484
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologic significance of the secretory A immunoglobulins.
    Bellanti JA
    Pediatrics; 1971 Nov; 48(5):715-29. PubMed ID: 4256343
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-neuraminidase antibody response in serum and nasal secretions following intranasal or subcutaneous inactivated A2-Hong Kong-68 influenza virus vaccine.
    Fedson DS; Fulk RV; Huber MA; Reisberg MA; Kasel JA
    J Immunol; 1971 Sep; 107(3):730-7. PubMed ID: 4999093
    [No Abstract]   [Full Text] [Related]  

  • 9. A stable antibody-sensitized erythrocyte diagnostic preparation for detection of rhinovirus type 17 and its antibody.
    Ponomareva TI; Levi MI; Dreizin RS
    Acta Virol; 1976 Jun; 20(3):232-7. PubMed ID: 9804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunological protection mechanisms in the airways.
    Bienenstock J
    Eur J Respir Dis Suppl; 1986; 147():62-71. PubMed ID: 3533594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine.
    Kasel JA; Hume EB; Fulk RV; Togo Y; Huber M; Hornick RB
    J Immunol; 1969 Mar; 102(3):555-62. PubMed ID: 5773312
    [No Abstract]   [Full Text] [Related]  

  • 12. Isolation of bovine rhinovirus from calves with respiratory disease.
    Shimizu Y; Narita M; Murase N
    Natl Inst Anim Health Q (Tokyo); 1974; 14(2):35-41. PubMed ID: 4374662
    [No Abstract]   [Full Text] [Related]  

  • 13. Parenteral inactivated rhinovirus vaccine: minimal protective effect.
    Douglas RG; Couch RB
    Proc Soc Exp Biol Med; 1972 Mar; 139(3):899-902. PubMed ID: 4336899
    [No Abstract]   [Full Text] [Related]  

  • 14. Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken.
    Xiaowen Z; Qinghua Y; Xiaofei Z; Qian Y
    Vaccine; 2009 Sep; 27(41):5628-32. PubMed ID: 19647063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein engineering to create biologically active peptides: recombinant human rhinoviruses that display peptide sequences.
    Smith AD; Arnold E; Arnold GF
    Behring Inst Mitt; 1997 Feb; (98):229-39. PubMed ID: 9382744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response effects of inactivated Newcastle disease vaccines: influence of serologic assay, time after vaccination, and type of chickens.
    Maas RA; Oei HL; Venema-Kemper S; Koch G; Bongers J
    Avian Dis; 1999; 43(4):670-7. PubMed ID: 10611983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhinovirus neutralizing antibody in tears, parotid saliva, nasal secretions and serum.
    Douglas RG; Rossen RD; Butler WT; Couch RB
    J Immunol; 1967 Aug; 99(2):297-303. PubMed ID: 4166403
    [No Abstract]   [Full Text] [Related]  

  • 18. Local antibody response to poliovaccine in the human female genital tract.
    Ogra PL; Ogra SS
    J Immunol; 1973 May; 110(5):1307-11. PubMed ID: 4633297
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of vaccines in respiratory virus infections;
    Tyrrell DA
    Trans Med Soc Lond; 1973; 89():263-70. PubMed ID: 4376628
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route.
    Perkins JC; Tucker DN; Knope HL; Wenzel RP; Hornick RB; Kapikian AZ; Chanock RM
    Am J Epidemiol; 1969 Oct; 90(4):319-26. PubMed ID: 4309899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.